



Neuren completes acquisition of Hamilton Pharmaceuticals

Key points:

- 13,625,443 ordinary shares issued to acquire Hamilton Pharmaceuticals
- US\$3 million received on issue of convertible notes

Tuesday 16 October 2007: Neuren Pharmaceuticals Limited (ASX:NEU) today completed the acquisition of United States based Hamilton Pharmaceuticals Inc ("Hamilton").

Neuren issued 13,625,443 ordinary shares in the scrip-for-scrip transaction to CNF Investments LLC, Index Ventures associated funds, and various Vivo Ventures biotechnology development funds. The number of shares issued was based on an agreed value of US\$4.1 million which represented a reduction in cost of approximately US\$300,000 since announcement of the binding terms sheet as a result of due diligence procedures on the acquired net assets of Hamilton.

In conjunction with the acquisition, CNF Investments and the Vivo Ventures biotechnology development funds have also today invested US\$3 million into Neuren through convertible notes.

Hamilton's principal asset is Motiva™, or nefiracetam, a novel cyclic gamma-aminobutyric acid, or GABA, derivative that Neuren intends to conduct a Phase 2 clinical trial for in post-stroke depression. Motiva™ has been administered to over 1,700 patients to date in previous Phase 1, 2a and 2b clinical trials in the U.S., Japan and China in which it demonstrated both safety and efficacy.

Neuren intends to release further details about Motiva™ and its intended clinical trial programme soon.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of brain injury and diseases and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition. Neuren has four lead candidates, Glypromate®, Motiva™, NNZ-2566, and NNZ-2591 targeting a range of acute and chronic neurological conditions. Neuren has commercial and development partnerships, including with the U.S. Army Walter Reed Army Institute of Research, Metabolic Pharmaceuticals, UCLA Medical Center and the National Trauma Research Institute in Melbourne.

For more information, please visit Neuren's website at www.neurenpharma.com

Contact details:

Neuren	Media and investor relations
David Clarke CEO T: 1 800 259 181 (Australia) T: +64 9 529 3942 (NZ) M: +64 21 988 052	Rebecca Wilson Buchan Consulting T: +61 2 9237 2800 M: +61 422 916 422